A phase II clinical trial studying the efficacy, safety, and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in Acute Myeloid Leukemia (AML) patients.
To assess the efficacy, safety, and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in AML patients
Overall Complete Response Rate: Defined as the proportion of patients achieving a complete remission or complete remission with incomplete recovery of neutrophils and platelets
To assess the safety and tolerability of AZD1152, alone and in combination with LDAC, compared to LDAC alone
Assessment of overall survival, duration of response, disease free survival, and time to complete response
Australia, France, Germany, Italy, Japan, Spain, United Kingdom, United States
AZD1152 is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.
For more information, please contact:
Cancer Study Locator service, sponsored by AstraZeneca at 1-877-400-4656 or via e-mail at: astrazeneca@emergingmed.com
To find available investigator site details, go to: www.clinicaltrials.gov
Download PDF (PDF— 
249 KB)